Xerient Pharma Ltd. is focused upon the treatment of pancreatic cancer through novel radiation treatment of the pancreas while protecting the adjacent bowel and stomach organs.

Xerient is repurposing an FDA-approved drug that when taken orally, rather than by injection, provides protection to the intestine.
Such protection enables the use of radiation at a level that ensures effective treatment of pancreatic cancer, and potentially other abdominal cancers.